A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 252 participants.

Also called NCT07613294

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 252 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07613294
  • EU CT 2025-524858-34-00
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Australia, Czechia, Hungary, Netherlands, Spain, United Kingdom (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07613294. Randomized; double masking; primary purpose treatment. Start 2026-06-01 (actual); primary completion 2029-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
Acronym
ACCLAIM-CTA
Condition
Atherosclerosis
Condition
Cardiovascular Diseases
Condition
Lipoprotein(a)
Intervention (Drug)
Lepodisiran
Intervention (Drug)
Placebo
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct07613294
Content hash
750650533fbb587011f59c3879080a7af1b11e86737ff76e99779196a18f5330